[HTML][HTML] Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe …
NF Marko, RJ Weil, JL Schroeder, FF Lang… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
NF Marko, RJ Weil, JL Schroeder, FF Lang, D Suki, RE Sawaya
Journal of clinical oncology, 2014•ncbi.nlm.nih.govPurpose Approximately 12,000 glioblastomas are diagnosed annually in the United States.
The median survival rate for this disease is 12 months, but individual survival rates can vary
with patient-specific factors, including extent of surgical resection (EOR). The goal of our
investigation is to develop a reliable strategy for personalized survival prediction and for
quantifying the relationship between survival, EOR, and adjuvant chemoradiotherapy.
The median survival rate for this disease is 12 months, but individual survival rates can vary
with patient-specific factors, including extent of surgical resection (EOR). The goal of our
investigation is to develop a reliable strategy for personalized survival prediction and for
quantifying the relationship between survival, EOR, and adjuvant chemoradiotherapy.
Abstract
Purpose
Approximately 12,000 glioblastomas are diagnosed annually in the United States. The median survival rate for this disease is 12 months, but individual survival rates can vary with patient-specific factors, including extent of surgical resection (EOR). The goal of our investigation is to develop a reliable strategy for personalized survival prediction and for quantifying the relationship between survival, EOR, and adjuvant chemoradiotherapy.
ncbi.nlm.nih.gov